Clinical trials have shown that a new, experimental drug given to the most seriously ill with coronavirus can prevent death.
Regeneron antiviral therapy, called REGEN-COV, has been found to save lives in cases where patients with severe COVID-19 symptoms do not develop antibodies on their own.
About 10,000 patients participated in the trials conducted in the United Kingdom under the guidance of the University of Oxford, from September 2020 until May this year.
It is a treatment that gives patients two artificial monoclonal antibodies, casirivimab and imdevimab, each of which attaches to a different part of the spike protein that the coronavirus uses to penetrate human cells.
In addition to preventing death, the length of stay of patients in the hospital was reduced, to be precise by four days.
It is not yet clear when the drug will be approved for use in the United Kingdom.